Head & Neck Cancers | Specialty

Nivolumab Improves OS, ORR in Phase III Head and Neck Cancer Study

June 7th 2016

Treatment with single-agent nivolumab improved overall survival and objective response rates compared with investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.

Dr. Pinheiro on Determinants of Cost in the Treatment of T1-T3 Oropharynx Cancer

May 27th 2016

A. Daniel Pinheiro, MD, physician, Otolaryngology, Mercy Clinic, discusses a study looking at the determinants of cost in the treatment of patients with T1 to T3 oropharynx cancer.

Novel Treatments, Effective Combinations Still Needed in Thyroid Cancer

May 26th 2016

Keith C. Bible, MD, PhD, discusses novel treatments he is excited about, the role of lenvatinib, and what the future may hold for thyroid cancer treatment.

Role of Cetuximab Expands in Head and Neck Cancer

May 25th 2016

James Melotek, MD, discusses two clinical trials looking at the impact of cetuximab in patients with squamous cell carcinoma of the head and neck.

Expert Discusses Promise of Nivolumab in Head and Neck Cancer

May 24th 2016

Robert Ferris, MD, PhD, explains the potential of nivolumab, its future, and its limitations in the treatment of patients with head and neck cancer.

FDA Grants Nivolumab Breakthrough Designation for Head and Neck Cancer

April 25th 2016

The FDA has granted a breakthrough therapy designation to nivolumab as a single-agent treatment for patients with recurrent or metastatic squamous cell carcinoma of the head and neck following a platinum-based therapy.

Dr. Ferris on CheckMate-141 Trial in Head and Neck Cancer

April 20th 2016

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the CheckMate-141 trial, which found that treatment with single-agent nivolumab (Opdivo) reduced the risk of death by 30% and doubled 1-year overall survival (OS) rates compared investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN).

Nivolumab Doubles 1-Year OS Rates in Head and Neck Cancer

April 19th 2016

Treatment with single-agent nivolumab reduced the risk of death by 30% and double 1-year overall survival rates compared investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.

Dr. Spencer on Radiation Therapy for Patients With Head and Neck Cancer

April 14th 2016

Sharon Spencer, MD, professor, chief of Medical Services, Ruby Meredith Outstanding Clinician Endowed Chair, University of Alabama at Birmingham School of Medicine, discusses the types of radiation therapy available to patients with head and neck cancer.

FDA Grants Priority Review to Pembrolizumab for Head and Neck Cancer

April 13th 2016

The FDA has granted a priority review designation to pembrolizumab (Keytruda) as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma.

Study Supports Immunotherapy/Radiation Combo in Head and Neck Cancer

April 8th 2016

Jonathan D. Schoenfeld, MD, discusses potential synergy between radiation therapy, given with or without chemotherapy, and immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck.

Challenging Genomic Blueprint of Head and Neck Cancers Emerges

April 8th 2016

Next-generation sequencing efforts focusing on the most common form, head and neck squamous cell carcinoma, are illuminating the hidden complexities of its genome.

Routine Imaging Not Necessary for HPV-Associated Oropharynx Cancer

April 6th 2016

Jessica Frakes, MD, explains findings from a study that examined treatment and follow-up for HPV-associated oropharynx cancer, and how they could impact clinical practice for the follow-up of patients with the disease.

Teaching Points and Conclusions in DTC

April 1st 2016

Emerging Therapies in Differentiated Thyroid Cancer

April 1st 2016

Sequencing in DTC: Lenvatinib and Sorafenib

April 1st 2016

TKI Dose Adjustment in Advanced DTC

April 1st 2016

Safety and Efficacy of Lenvatinib in Advanced DTC

April 1st 2016

Efficacy and Toxicity of Sorafenib in Advanced DTC

April 1st 2016

TKI Therapy for Advanced Thyroid Cancer

April 1st 2016